2017 seasonal influenza vaccines
Influenza vaccines can change from year to year as new strains of influenza virus appear. This is one reason vaccination against influenza is given every year.
The Australian Influenza Vaccine Committee (AIVC) has reviewed and evaluated data relating to the strains of influenza that were circulating in Australia and the Southern Hemisphere in the winter of 2016. Based on this review, the AIVC has recommended that the TGA adopt the September 2016 World Health Organization (WHO) recommendations for the strains to be covered by the 2017 seasonal influenza vaccines. Details of the strains were announced on the TGA website on 25 October 2016.
This year, only quadrivalent vaccines will be available. These vaccines help protect against four strains of the influenza virus.
Quadrivalent vaccines include two influenza A strains and two influenza B strains. For more information see Influenza vaccine: the annual Southern Hemisphere influenza vaccine production and the regulatory approval timeline.
For the 2017 influenza season, the TGA has registered four vaccines which will be available for use in the following age groups:
|GlaxoSmithKline||Fluarix Tetra||3 years and over|
|Sanofi-Aventis||FluQuadri Junior*||6-35 months (<3 years)|
|FluQuadri||3 years and over|
|Seqirus||Afluria Quad||18 years and over|
* Guidance for the dose in children aged 6-35 months is available in the Product Information.
For further information on individual vaccines, please refer to the relevant Product Information document or Consumer Medicine Information document.
For further information about the use of seasonal influenza vaccines in children, please refer to the TGA web statement.
Further information for health professionals is available from the Australian Technical Advisory Group on Immunisation (ATAGI) Influenza Statement.
In conjunction with the Office of Health Protection and state and territory health authorities, the TGA will be closely monitoring adverse event reports during the 2017 influenza vaccination program.
The 2017 National Seasonal Influenza Immunisation Program will start from April 2017.
Reporting of adverse events following influenza vaccine
Health professionals and consumers are encouraged to report all adverse events associated with influenza vaccination in patients of any age to the TGA or through the current arrangements in their State or Territory.
All reports contribute to the TGA's ongoing monitoring of the safety of influenza vaccines.
The TGA cannot give advice about an individual's medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a vaccine or medicine.